Encision Reports Second Quarter Fiscal Year 2019 Results

BOULDER, Colo., Nov. 6, 2018 /PRNewswire/ -- Encision, Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2019 second quarter that ended September 30, 2018.

The Company posted quarterly net revenue of $2.20 million for a quarterly net income of $12 thousand, or $0.00 per diluted share. These results compare to net revenue of $2.16 million for a quarterly net income of $116 thousand, or $0.01 per diluted share, in the year-ago quarter. Net revenue for last year's quarter included net revenue of $74 thousand from an order for non-AEM product. Gross margin on net revenue was 55% in the fiscal 2019 second quarter and 58% in the fiscal 2018 second quarter. Gross margin on net revenue was lower in the current quarter as a result of product mix and higher material cost.

The Company posted six months net revenue of $4.60 million for a six months net income of $31 thousand, or $0.00 per diluted share. These results compare to net revenue of $4.53 million for a six months net income of $298 thousand, or $0.03 per diluted share, in the year-ago six months. Net revenue for last year's six months included net revenue of $329 thousand from an order for non-AEM product. Gross margin on net revenue was 54% in the fiscal 2019 six months and 58% in the fiscal 2018 six months. Gross margin on net revenue was lower in the current six months as a result of product mix and higher material cost.

"We had strong AEM product revenue growth of 5% year over year and posted a modest profit for the quarter," said Greg Trudel, President and CEO of Encision Inc. "The increase of sales and marketing expense reflects the costs of increased direct sales representation, higher commissions on higher revenue, and higher commission rates on exceeded quotas. The investment to fortify our sales channel with direct sales representation to fill strategic gaps and supplant underperforming distribution relationships is showing promising results and we look forward to developing that strata further. Our sales team continues to deliver new account conversions and we are excited over the growing pipeline and sales momentum."

"During the six months, the FDA issued a Safety Communication, 'Recommendations to Reduce Surgical Fires and Related Patient Injury: FDA Safety Communication' that describes the dangers of monopolar electrosurgery and the means to mitigate or eliminate this risk. The Safety Communication states that, 'In addition to serving as an ignition source, monopolar energy use can directly result in unintended patient burns from capacitive coupling and intra-operative insulation failure. If a monopolar electrosurgical units (ESU) is used: Do not activate when near or in contact with other instruments.' This Safety Communication will help to build awareness of the dangers of stray energy among health care providers. We see that health care providers are becoming more willing to discuss stray energy risks and to consider technology solutions to safeguard their patients. Encision applauds the efforts of the FDA to safeguard the American public from this very real and prevalent surgical risk."  The Safety Communication was released by the FDA on May 29, 2018. It is on the FDA's website at: https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm608637.htm.

Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2018 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:  Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

Encision Inc.

Unaudited Condensed Statements of Operations

(in thousands, except per share information)

 
   

Three Months Ended

Six Months Ended

   

September 30,
2018

 

September 30,
2017

 

September 30,
2018

 

September 30,
2017

Net revenue

 

$2,197

 

$2,163

 

$4,601

 

$4,526

Cost of revenue

 

992

 

904

 

2,095

 

1,923

Gross profit

 

1,205

 

1,259

 

2,506

 

2,603

Operating expenses:

               

    Sales and marketing

 

656

 

574

 

1,432

 

1,176

    General and administrative

 

322

 

366

 

642

 

689

    Research and development

 

187

 

190

 

353

 

411

        Total operating expenses

 

1,165

 

1,130

 

2,427

 

2,276

Operating income

 

40

 

129

 

79

 

327

Interest expense and other expense, net

 

(28)

 

(13)

 

(48)

 

(29)

Income before provision for income taxes

 

12

 

116

 

31

 

298

Provision for income taxes

 

––

 

––

 

––

 

––

Net income

 

$12

 

$116

 

$ 31

 

$ 298

Net income per share—basic and diluted

 

$0.00

 

$0.01

 

$0.00

 

$0.03

Weighted average number of shares—basic

 

10,683

 

10,683

 

10,683

 

10,683

Weighted average number of shares—diluted

 

10,718

 

10,692

 

10,711

 

10,692

                 

 

Encision Inc.

Unaudited Condensed Balance Sheets

 (in thousands)

 
   

September 30,
2018

 

March 31,
2018

ASSETS

       

Cash and cash equivalents

 

$     162

 

$    114

Restricted cash

 

25

 

25

Accounts receivable, net

 

1,107

 

963

Inventories, net

 

1,368

 

1,437

Prepaid expenses

 

99

 

75

    Total current assets

 

2,761

 

2,614

Equipment, net

 

281

 

349

Patents, net

 

261

 

270

Other assets

 

19

 

19

    Total assets

 

$ 3,322

 

$ 3,252

LIABILITIES AND SHAREHOLDERS' EQUITY

       

Accounts payable

 

$   569

 

$   467

Accrued compensation

 

285

 

257

Other accrued liabilities

 

161

 

285

Deferred rent

 

––

 

30

    Total current liabilities

 

1,015

 

1,039

Deferred rent

 

46

 

10

    Total liabilities

 

1,061

 

1,049

Common stock and additional paid-in capital

 

23,844

 

23,818

Accumulated (deficit)

 

(21,583)

 

(21,614)

    Total shareholders' equity

 

2,261

 

2,204

    Total liabilities and shareholders' equity

 

$ 3,322

 

$ 3,252

 

Encision Inc.

Unaudited Condensed Statements of Cash Flows

 (in thousands)

 
   

Six Months Ended

   

September 30,
2018

 

   September 30,
2017

Operating activities:

       

    Net income

 

$ 31

 

$  298

    Adjustments to reconcile net income to cash generated by operating activities:

       

    Depreciation and amortization

 

92

 

102

    Share-based compensation expense

 

26

 

33

    (Recovery from) provision for doubtful accounts, net

 

(1)

 

(24)

    (Recovery from) inventory obsolescence, net

 

4

 

(10)

    Changes in operating assets and liabilities:

       

        Accounts receivable     

 

(143)

 

146

        Inventories

 

65

 

(76)

        Prepaid expenses and other assets

 

(24)

 

(92)

        Accounts payable

 

103

 

3

        Accrued compensation and other accrued liabilities

 

(90)

 

(6)

            Net cash generated by operating activities

 

63

 

374

         

Investing activities:

       

    Acquisition of property and equipment

 

(10)

 

(16)

    Patent costs

 

(5)

 

(24)

            Net cash (used in) investing activities

 

(15)

 

(40)

         

Financing activities:

       

    Paydown of credit facility, net change

 

––

 

(275)

            Net cash (used in) financing activities

 

––

 

(275)

         

Net increase in cash, cash equivalents, and restricted cash

 

48

 

59

Cash, cash equivalents, and restricted cash, beginning of period

 

139

 

95

Cash, cash equivalents, and restricted cash, end of period

 

$    187

 

$ 154

           

 

Cision View original content:http://www.prnewswire.com/news-releases/encision-reports-second-quarter-fiscal-year-2019-results-300743143.html

SOURCE Encision Inc.

   
Company Codes: OTC-PINK:ECIA  

Back to news